The report analyzes and presents an overview of Virus-Like Particles (VLPs) market worldwide. "Virus-like particles or VLPs bear high structural resemblance to viruses, though completely non-infectious in nature due to the absence of viral genetic material. While lacking the DNA material, VLPs retain key immunological characteristics of viruses including particulate structures; repetitive surfaces; and capability to induce innate immunity by activating molecular-pattern pathogen-associated recognition receptors."
The report also provides a review of types, medium of production, quantification, applications, and advantages of VLPs over conventional vaccines along with strategic industry activities of major companies worldwide. In addition, 10 companies operating in the Direct Attached Storage (DAS) arena worldwide including Cytos Biotechnology AG, Medicago Inc., Novavax Inc., Redbiotec AG, Virometix AG, VLPbio - The Vaccines Company and other are profiled.